Holen Sie sich die Stockscreener-App
37.03
2.58%
0.93
Handel nachbörslich:
37.03
Schlusskurs vom Vortag:
$36.10
Offen:
$35.98
24-Stunden-Volumen:
234.07K
Relative Volume:
0.48
Marktkapitalisierung:
$754.30M
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-4.0382
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
-1.73%
1M Leistung:
+1.70%
6M Leistung:
-53.39%
1J Leistung:
-18.09%
1-Tages-Spanne:
$35.21
$37.55
1-Wochen-Bereich:
$35.21
$38.86
52-Wochen-Spanne:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
37.03 | 767.50M | 1.77M | -123.74M | -95.21M | -9.17 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
(PRAX) Trading Report - news.stocktradersdaily.com
Deutsche Bank AG Buys 5,009 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines to Participate in Upcoming Conferences - GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Conferences | PRAX Stock News - GuruFocus
What is Chardan Capital’s Forecast for PRAX FY2025 Earnings? - Defense World
Dimensional Fund Advisors LP Decreases Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Northern Trust Corp Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Investment Report - news.stocktradersdaily.com
Piper Sandler maintains Praxis stock at $270 target, bullish stance By Investing.com - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Research Coverage Started at Chardan Capital - Defense World
Praxis Precision Medicines (PRAX) to Release Earnings on Monday - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analytical Lens: Exploring Praxis Precision Medicines Inc (PRAX)’s Financial Story Through Ratios - DWinneX
3,008 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Bought by Envestnet Asset Management Inc. - Defense World
Wedbush Has Positive Outlook for PRAX Q2 Earnings - Defense World
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - NewsBreak: Local News & Alerts
HC Wainwright Issues Negative Forecast for PRAX Earnings - Defense World
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
Chardan Capital Initiates Coverage on PRAX with a Buy Rating | PRAX Stock News - GuruFocus
Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target - marketscreener.com
Chardan Initiates Coverage on Praxis Precision (PRAX) with Buy Rating | PRAX Stock News - GuruFocus
Analysts Issue Forecasts for PRAX Q4 Earnings - Defense World
HC Wainwright Has Bearish Forecast for PRAX FY2029 Earnings - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $28.00 Price Target at Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (NASDAQ:PRAX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event - GlobeNewswire
Praxis Precision Medicines: Advancements and Financial Outlook - TipRanks
Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX - GuruFocus
Wedbush Adjusts Price Target for Praxis Precision Medicine (PRAX) | PRAX Stock News - GuruFocus
PRAX Stock Target Increased by Baird Amid Positive Epilepsy Drug Outlook | PRAX Stock News - GuruFocus
Wedbush Lifts Price Target on Praxis Precision Medicines to $28 From $26, Keeps Underperform Rating - marketscreener.com
PRAX Unveils Progress in DEE Clinical Programs | PRAX Stock News - GuruFocus
Clinical Trial Success: Praxis's DEE Drug Cuts Seizures by 90%, Eyes $3B Market Opportunity - Stock Titan
Praxis Precision Medicine (PRAX): Buy Rating Reiterated by Needham | PRAX Stock News - GuruFocus
Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024) - Yahoo
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PRAX Stock News - GuruFocus
Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines Awards 3,688 Restricted Stock Units to 5 New Non-Executive Hires - Stock Titan
Praxis Precision Medicines Provides Corporate Update and Reports - GuruFocus
PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfoli - GuruFocus
PRAX Revenue Falls Short as Company Focuses on Epilepsy Portfolio | PRAX Stock News - GuruFocus
Praxis Precision Medicines, Inc. SEC 10-Q Report - TradingView
Praxis Precision Medicines Reports Significant Progress and Upcoming Milestones in Epilepsy Portfolio - Nasdaq
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Wells Fargo & Company MN Boosts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts - Benzinga
PRAX: HC Wainwright Reiterates Buy Rating and $105 Price Target | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc (PRAX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
8.70%
1.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):